Treatment-resistant Depression - Epidemiology Forecast - 2032

This ‘Treatment Resistant Depression (TRD) Overview - Epidemiology Forecast-2032' report delivers an in-depth understanding of the Treatment Resistant Depression (TRD), historical and forecasted epidemiology as well as the Treatment Resistant Depression (TRD) epidemiology trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Treatment Resistant Depression (TRD) Understanding

Treatment Resistant Depression (TRD) Overview

Treatment-resistant Depression (TRD) typically refers to an inadequate response to at least two antidepressant medications used for a sufficient time at an adequate dose with the adequate affirmation of treatment adherence.

The European Union's Committee for Human Proprietary Medicinal Products (CHMP) defines TRD as follows: ‘A patient is considered therapy-resistant when consecutive treatments with two products of different classes, used for a sufficient time at an adequate dose, fail to induce an acceptable effect.' Unfortunately, this broad definition does not properly specify what a sufficient length of time,' ‘adequate dose,' and ‘acceptable effect' means.

TRD is usually linked to higher rates of comorbidity, particularly with other psychiatric disorders, chronic pain, and fibromyalgia. On the other hand, the impact of physical and psychiatric illness comorbidities is much higher among TRD patients. Some environmental factors related to TRD are lower socioeconomic status, non-supportive social environment, family conflicts, chronic stressors, multiple loss events, lower levels of education and social support, and work dysfunction.

TRD Diagnosis

A diagnostic evaluation is required to treat and manage patients who do not respond well to medication. The possible role of several contributing factors, such as medical and psychiatric comorbidity, must be considered. Accurate and systematic TRD evaluation is a problem for clinicians and researchers, with clinician-rated or self-rated instruments being potentially beneficial. There may be varying degrees of treatment resistance. Some staging methods for assessing treatment resistance in depression are being developed, but they must be empirically verified.

Treatment Resistant Depression (TRD) Epidemiology Perspective

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of TRD, Gender-specific Cases of TRD, and Age-specific Cases of TRD scenario in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

Treatment Resistant Depression (TRD) Detailed Epidemiology Segmentation

• The total diagnosed prevalent cases of TRD in the 7MM were approximately 6,409,000 cases in 2022 and are projected to increase during the forecast period (2023-2032).
• The United States contributed to the largest number of diagnosed prevalent cases of TRD (~71%) in the 7MM in 2022. Whereas EU4 and the UK, and Japan accounted for around 25% and 4% of the total diagnosed prevalent cases of TRD in the 7MM, respectively, in 2022.
• Among the EU4 countries, Germany accounted for the highest number of total diagnosed prevalent cases of TRD, whereas Italy accounted for the lowest number of cases in 2022.
• The estimates that around 512,000 cases and ~1,117,000 cases of TRD were observed in males and females, respectively, in EU4 and the UK in 2022. Females contributed approximately 71% to the overall prevalent cases of TRD in the 7MM.
• In 2022, the maximum number of cases of TRD was found in the age category of 50-60 years, and the least number of cases were found in 18-29 years age category in the US.

Scope of the Report

• The report covers a descriptive overview of Treatment Resistant Depression (TRD), explaining its types, causes, symptoms, and diagnosis.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 countries (Germany, France, Italy, Spain), the United Kingdom, and Japan.
• The report assesses the Treatment Resistant Depression (TRD) risks and burden.
• The report provides the segmentation of the epidemiology for 7MM segmented by ‘Total Diagnosed Prevalent Cases of TRD, Gender-specific Cases of TRD, and Age-specific Cases of TRD'.

Report Highlights

• 10-Year Forecast of Treatment Resistant Depression (TRD)
• 7MM Coverage
• Total Diagnosed Prevalent Cases of TRD
• Gender-specific Cases of TRD
• Age-specific Cases of TRD

Key Questions Answered

• What are the risk and burdens of Treatment Resistant Depression (TRD)?
• What is the historical Treatment Resistant Depression (TRD) patient pool in the United States, EU4 (Germany, France, Italy, Spain), the UK, and Japan?
• What would be the forecasted patient pool of Treatment Resistant Depression (TRD) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Treatment Resistant Depression (TRD)?
• Out of the countries mentioned above, which country would have the highest cases of Treatment Resistant Depression (TRD) during the forecast period (2023-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2023-2032)?

Reasons to Buy

The Treatment Resistant Depression (TRD) report will allow the user to -

• Develop business strategies by understanding the trends, shaping and driving the 7MM Treatment Resistant Depression (TRD) epidemiology.
• The Treatment Resistant Depression (TRD) epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The Treatment Resistant Depression (TRD) epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Geographies Covered

• The United States
• EU4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan

Study Period: 2019-2032